Drugs / PRGF-Endoret
PRGF-Endoret
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03387501 | May 2019 → Jul 2022 | female infertility | Sara Rafael Fernandez | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04093583 | Nov 2019 → Jan 2025 | — | Fundación Eduardo Anitua | Completed | No outcome recorded |
| Phase 3 | NCT02996760 | Mar 2018 → Dec 2021 | — | IVI Bilbao | Terminated | No outcome recorded Stop: Enrollment |
| Phase 41 trial | ||||||
| Phase 4 | NCT02707120 | Jan 2018 → Jan 2019 | neurotrophic keratopathy | Biotechnology Institute IMASD | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase not applicable1 trial | ||||||
| — | NCT01465399 | Oct 2011 → Dec 2012 | alveolar periostitis | Fundación Eduardo Anitua | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 0 | NCT06664268 Comparator | Nov 2024 → Nov 2025 overdue | reactive cutaneous fibrous lesion | Assiut University | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRGF-Endoret | “knowing the clinical value of using the PRGF-Endoret therapy” NCT02996760 ↗ |
| Known as | Plasma rich in growth factors | “Efficacy and Safety of Plasma Rich in Growth Factors (PRGF-Endoret) Eye-drops in the Treatment of Neurotrophic Keratitis” NCT02707120 ↗2“Plasma rich in growth factors (PRGF-Endoret)” NCT03387501 ↗ “Plasma rich in growth factors (PRGF-Endoret)” NCT06664268 ↗ |
| Known as | PRP | “Alveolar ridge preservation with a PRP (PRGF-Endoret)” NCT04093583 ↗ |
| Modality | Protein / enzyme biologic | “Plasma rich in growth factors (PRGF-Endoret) represent a new technology using autologous proteins, growth factors and biomaterials as therapeutic formulations for different...” NCT02707120 ↗ |
| Route | Topical | “Active treatment will be PRP eye drops obtained by the PRGF-Endoret system.” NCT02707120 ↗ |